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Abstract
Background: Geohelminth infections are highly prevalent infectious diseases of childhood in many regions of the
Tropics, and are associated with significant morbidity especially among pre-school and school-age children. There is
growing concern that geohelminth infections, particularly exposures occurring during early life in utero through
maternal infections or during infancy, may affect vaccine immunogenicity in populations among whom these
infections are endemic. Further, the low prevalence of allergic disease in the rural Tropics has been attributed to the
immune modulatory effects of these infections and there is concern that widespread use of anthelmintic treatment in
high-risk groups may be associated with an increase in the prevalence of allergic diseases. Because the most widely
used vaccines are administered during the first year of life and the antecedents of allergic disease are considered to
occur in early childhood, the present study has been designed to investigate the impact of early exposures to
geohelminths on the development of protective immunity to vaccines, allergic sensitization, and allergic disease.
Methods/Design: A cohort of 2,403 neonates followed up to 8 years of age. Primary exposures are infections with
geohelminth parasites during the last trimester of pregnancy and the first 2 years of life. Primary study outcomes
are the development of protective immunity to common childhood vaccines (i.e. rotavirus, Haemophilus influenzae
type B, Hepatitis B, tetanus toxoid, and oral poliovirus type 3) during the first 5 years of life, the development of
eczema by 3 years of age, the development of allergen skin test reactivity at 5 years of age, and the development
of asthma at 5 and 8 years of age. Potential immunological mechanisms by which geohelminth infections may
affect the study outcomes will be investigated also.
Discussion: The study will provide information on the potential effects of early exposures to geohelminths (during
pregnancy and the first 2 years of life) on the development of vaccine immunity and allergy. The data will inform an
ongoing debate of potential effects of geohelminths on child health and will contribute to policy decisions on new
interventions designed to improve vaccine immunogenicity and protect against the development of allergic diseases.
Trial registration: Current Controlled Trials ISRCTN41239086.
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Background
The geohelminth (also known as intestinal or soil-trans-
mitted helminth infections) parasites, Ascaris lumbri-
coides, Trichuris trichiura, hookworm, and Stronglyoides
stercoralis, are common infectious diseases of childhood
in tropical regions and are estimated to infect over 2 bil-
lion humans worldwide [1]. Geohelminth infections are
considered to cause significant morbidity in endemic
areas through affects on nutrition, growth, and cognition
affecting school performance [2].
Geohelminth infections induce an immune responses in
humans characterized by elevated IgE levels, eosinophilia,
and increased production of Th2 cytokines from periph-
eral blood leukocytes in response to stimulation by para-
site antigen [3]. While initial exposures to these parasites
may be associated with enhanced allergic inflammatory
responses to the parasite, in long-term infections and with
repeated exposures, the host inflammatory response
becomes more tightly controlled [4,5]. Chronic infections
have potent regulatory effects on anti-parasite inflamma-
tory responses [5,6], being associated with a modulated or
‘modified’ Th2 responses that may facilitate parasite survi-
val but protect the host from damaging immune-mediated
disease [4]. The regulation of host immunity by chronic
geohelminth infections may not just affect responses to
parasite antigens but also other exogenous antigens such
as the antigenic constituents of vaccines and aeroallergens.
Such effects may contribute to the impaired vaccine
immunogenicity [7-10] and decreased prevalence of aller-
gic diseases [5,11] reported from the rural Tropics.
The prevalence of allergic diseases has increased over
the past 40 years and has reached epidemic levels in
many developed countries such as the UK, [12] where
they are now the most prevalent chronic diseases of
childhood. International surveys showed that the preva-
lence of asthma varied 20-fold between countries, ran-
ging 1.6-36.8% [13], and a surprising finding was the
high prevalence of asthma in urban centres in Latin
America with prevalence rates as high as those reported
from traditional high prevalence countries [13,14].
The causes of the high prevalence of allergic diseases
in developed countries and the increasing prevalence in
many developing countries are not known. The most
widely accepted explanation is the ‘hygiene hypothesis’
that has attributed the increases in prevalence to a
decline in infectious and microbial exposures during
childhood [12,15,16]. This was initially explained in the
context of the effects of early infectious exposures on
the Th1/Th2 cytokine balance: a greater infectious bur-
den induces stronger Th1 responses that counterba-
lanced the effects of pro-allergic Th2 responses. The
observation that chronic helminth infections, that
induce strong Th2 immunity, appeared to protect
against allergy stimulated a re-working of the hypothesis
to emphasize the role of immune regulatory mechan-
isms to control Th1 and Th2-mediated inflammation
[17,18]. Current thinking has emphasized the impor-
tance of multiple early infectious exposures including
helminths in the induction of an immune regulatory
network [6,11,19] that controls inflammatory responses
to both Th1 and Th2-inducing stimuli. Important med-
iators of immune regulation may include subsets of reg-
ulatory immune cells [4,20-23].
There is evidence from experimental animal models
that intestinal and tissue helminth infections have dele-
terious effects on vaccine immune responses [24,25].
Further, intestinal helminth infections have been shown
to either enhance [26,27] or suppress [27-29] allergic
inflammatory responses in different experimental mod-
els of allergic inflammation. Studies conducted in chil-
dren and adults indicate that concurrent geohelminth
infections can suppress protective immune responses to
both parenteral [30,31] and oral [32] vaccines and are
inversely associated with the prevalence of allergen skin
test reactivity [5,33] used as a marker for atopy or aller-
gic sensitization. Geohelminth infections have also been
associated with either a reduced [34] or increased preva-
lence [5,34] of asthma depending on the prevalence and
type of geohelminth parasite present.
Because the antecedents of allergic diseases are con-
sidered to occur in early life and most vaccines are
administered during the first year of life before geohel-
minth infections are acquired, there is interest in the
potential effects of maternal geohelminth infections on
infant morbidity [35], and the effects of such exposures
on vaccine immune responses during infancy [31,35-37]
and the development of allergic sensitization and allergic
diseases [5,35,38,39]. There is evidence that maternal
helminth infections bias the fetal immune response [31]
an effect that persists into infancy and that may inter-
fere with protective immunity associated with vaccines
such as BCG [40]. Similarly, maternal ascariasis is asso-
ciated with sensitization to A. lumbricoides antigens in
newborns [41], although the long-term consequences of
such sensitization are unclear.
The present study is investigating the potential effects
of intrauterine and postnatal exposures to geohelminths
on vaccine immune responses in infancy, and the devel-
opment of allergic sensitization and allergic inflamma-
tory diseases in childhood. The study will also
investigate the immunological mechanisms by which
such effects occur. The findings of this study have clear
policy implications given that anthelmintic treatment of
school-age children for the control of geohelminth
infections is now a widely implemented public health
strategy [42,43], and the use of anthelmintic treatment
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during pregnancy has been advocated to improve the
health of mothers and infants [43,44]. Few opportunities,
therefore, still exist to study the development of allergic
disease in early childhood in the context of endemic
geohelminth infections.
Hypotheses
This study has been designed to investigate four specific
hypotheses relating to the effect of maternal and infant
infections with geohelminths on host immune responses
and development of allergic inflammatory diseases: 1)
chronic exposures to geohelminth infections (i.e. mater-
nal geohelminth infections and infant geohelminth infec-
tions within the first 2 years of life) suppress immune
responses to childhood vaccines; 2) chronic exposures to
geohelminth infections suppress aeroallergen skin test
reactivity; 3) chronic exposures to geohelminth infections
protects against the development of eczema; and 4)
chronic exposures to geohelminth infections protect
against the development of asthma but non-chronic
exposures (i.e. later childhood exposures occurring after
2 years in the absence of maternal geohelminth infec-
tions) increase the risk of asthma.
Methods/design
Study design
The study is a birth cohort of 2,403 children recruited
from around the time of birth in HPAB over the period
November 2005 to December 2009. The recruitment
area for the cohort is defined geographically by the
boundaries of the District of Quinindé, Esmeraldas Pro-
vince in Northern coastal Ecuador (Figure 1). The
 

Figure 1 Study site. A. Map of Ecuador showing location of District of Quinindé, Esmeraldas Province (black oval) (Courtesy of The General
Libraries, The University of Texas at Austin). The recruitment area for the cohort was defined by the geographic boundaries of this district. B.
Map showing parishes the District of Quinindé including La Concordia. H-Hospital Padre Alberto Buffoni. C. Geographic location of households of
cohort infants.
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primary exposures are maternal and infant infections
with geohelminths and the primary outcomes are vac-
cine immunity, atopy and allergic disease.
Study population and area
The Province is one of the poorest regions of Ecuador,
with a per capita income of less than US$2,000 in 2005.
Quinindé is a rural District that covers an area of 3,471
km2 and includes 1 urban (the town of Quinindé) and 6
rural parishes with an estimated population of 150,000.
The District is located in an area of (formerly) equator-
ial rainforest that has largely been cleared, at an altitude
of approximately 100 m and average annual day tem-
perature of 30°C and 75% humidity. The District has an
ethnically mixed population of mestizos (90%), Afro-
Ecuadorians (7%), and Amerindians (3%). Twenty-two
percent of the population is estimated to be urban (Qui-
nindé town) and 78% rural. In the town of Quinindé,
approximately 90% of the population have access to
electricity, 60% to treated drinking water, 40% to sanita-
tion; 60% to solid waste disposal services. In contrast, in
the rural areas, 10% have access to electricity and none
have access to other services. The main sources of
income are derived from African palm oil and fruit cul-
tivation, cattle, and extraction of timber. The study is
based at the Hospital “Padre Alberto Buffoni” (HPAB)
(H in Figure 1) in Quinindé town. HPAB is the only
Hospital serving the District and the only health centre
with maternity services.
Inclusion criteria
Although assessments and sampling are conducted dur-
ing pregnancy, only a proportion of pregnant mothers
attend antenatal clinics, and formal recruitment into the
cohort occurs around the time of birth. Entry criteria
into the study are: 1) healthy normal baby less than 14
days old; 2) at least one stool sample collected from the
mother; 3) the family has lived in the District for the
last 2 years and does not plan to move out of the Dis-
trict over the following 3 years; 4) the home is accessi-
ble; and 5) the mother is 17 years or older.
Sampling and evaluations
The sampling and examination schedule for follow-up is
shown in Table 1. Evaluations are conducted at birth, 2
weeks, 3, 7, 13, 18, 24 and 30 months, and at 3, 5, and 8
years through home visits and scheduled visits at the
ECUAVIDA outpatient clinic at HPAB. More detailed
immunologic evaluations are performed in an immunol-
ogy sub-cohort (ISC) of the last 295 infants recruited
Table 1 Sampling schedule for ECUAVIDA cohort
Visit Ante-natal Birth < 2 wks 3 mths 7 mths 13 mths 24 mths 3 years 5 yrs 8 yrs
Site HPAB HPAB Home HPAB/home HPAB/home Home HPAB/home HPAB/home HPAB/home Home
Child
Questionnaire X X X X X X X X
Faeces X X X X X X X X X
Blood Xa X X X X X X X
Clinical exam X X X X X X X X
Anthropometry X X X X X X
SPT X X X X
PFTs/BHR X
Mantoux test X
Mother
Questionnaire X X X X
Faeces X X X
Blood X
SPT
Father
Faeces X X
SPT
Household
GPS Xb Xb
Dust Xb
Faeces X
Stool samples are collected also at 18 and 30 months. HPAB-Hospital Padre Alberto Buffoni in Quinindé, Esmeraldas Province; SPT-allergen skin test reactivity;
PFTs-pulmonary function tests measured by spirometry; BHR-bronchial hyperresponsiveness or evidence of reversibility following b2 agonist; GPS-geographic
positioning system measurements for mapping of households. a immunology sub-cohort only. b measurements repeated for change of address.
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using blood samples collected at birth, 7, 13 and 24
months, and at 3, 5 and 8 years. A surveillance sub-cohort
of 195 newborns living within the town of Quinindé are
being followed-up actively and sampled for viral respira-
tory tract infections (influenza viruses, respiratory syncytial
viruses, adenoviruses, and rhinoviruses) using nasal swabs
and diarrheal illnesses (rotavirus and norovirus) using
stool samples during the first 2 years of life. Aliquots of all
stool samples collected and hypopharyngeal swabs (at rou-
tine sampling times) are being stored for future analyses of
bacterial microbiota.
Vaccination schedule
All vaccines are provided free of charge by the Ministry
of Public Health at the vaccination clinic at HPAB. The
vaccination schedule is: birth-BCG; 2 months and 4
months-pentavalent (Quinvaxem [DPT-HepB-Hib],
Novartis), trivalent oral poliovirus vaccine (Chiron),
rotavirus (Rotarix, GSK); 6 months-pentavalent, OPV;
12 months-measles-mumps-rubella (Serum Institute of
India [SII]); and 18 months-DT (SII) and OPV.
Measurement and definition of geohelminth exposures
Stool samples to measure geohelminth infections have
been collected from mothers in the third trimester of
pregnancy (stool samples collected after birth and before
the child is 14 days old are considered to represent a
third trimester stool sample where the mother has not
received anthelmintic treatment) and from infants at 3,
7, 13, 18, 24, and 30 months, and at 3, 5, and 8 years.
Stool samples are analysed using a combination of
standard methods including direct saline mounts, the
modified Kato-Katz method, formol-ether concentration,
and carbon-coproculture methods [45]. Geohelminth
infectious exposures will be defined as follows: 1) mater-
nal geohelminth infections-presence of any geohelminth
infection detected during the 3rd trimester of pregnancy;
and 2) infant geohelminth infections-presence of any
geohelminth infections detected during the first 2 years
of life.
Measurement and definitions of study outcomes
Primary study outcomes
1. Vaccine immune responses: vaccine immunity will be
measured by the presence of protective antibody levels
measured as follows-1) IgG to tetanus toxoid as
described previously [46]. Immune protection will be
defined > 0.15 IU/ml; 2) titer of neutralizing antibodies
to OPV type 3 using the microneutralization assay at
the Health Protection Agency (HPA), London, UK. Pro-
tection will be defined as OPV type 3 virus neutraliza-
tion at 100TCID50 at serum dilution ≥ 1:8 dilution; 3)
IgA to rotavirus (HPA); protection indicated by titers ≥
20 U/mL; 4) IgG to polyribosylribitol phosphate of
Haemophilus influenzae type B (Binding site, Birming-
ham, UK); protection > 0.15 mg/mL; 5) anti-HBS IgG
antibodies (Architect, Abbott Diagnostics, Sligo, Ireland),
protection > 10 IU/mL IgG. Plasma samples collected at
24 months and 5 years will be used to measure short-
term (24 months) and long-term (5 years) antibody-
mediated protective immunity. Vaccine responses to Hib
and rotavirus will be measured only at 7 months to dis-
tinguish vaccine-mediated responses from those
acquired from natural exposures to these infections.
2. Atopy: defined by the presence of allergen skin test
reactivity at 5 years to any of the following aeroaller-
gens: Dermatophagoides pteronyssinus/farinae mix,
American cockroach (Periplaneta americana), fungi
mix, dog, cat, and mixed grass pollen. A positive test is
defined by the presence of a skin wheal ≥ 3 mm greater
than saline control. All skin testing will be conducted by
trained physicians and will be supervised by a highly
experienced clinical investigator (MEC).
3. Eczema: Eczema has been assessed by questionnaire
and physical examination using standardized instruments
based on the United Kingdom Working Party (UKWP)
criteria/Nottingham protocol [47]. Cases of flexural der-
matitis are assessed further for severity using the
SCORAD protocol [48]. Evaluations for eczema are per-
formed at 7, 13, 24, and 36 months. Infants presenting to
the ECUAVIDA outpatient clinic with skin complaints
are also assessed for eczema. All clinical evaluations are
done by trained physicians using standardized protocols.
Eczema will be defined by at least one presentation dur-
ing the first 3 years of life of an itchy skin condition plus
3 or more of the following: i) history of involvement of
flexural sites including cheeks; ii) history of atopic disease
in first degree relative: iii) a history of generally dry skin
in last year; and iv) visible flexural dermatitis or dermati-
tis affecting cheeks/forehead and outer limbs.
4. Asthma: Asthma will be measured at 5 and 8 years
using the ISAAC phase II questionnaire [49] and
defined by the presence of wheeze within the previous
12 months plus: either a previous history of wheeze
within the previous 12 months (at 13, 24, and 36
months) or a previous ECUAVIDA clinic diagnosis of
asthma. Non-atopic and atopic asthma will be defined
by the presence or absence, respectively, of allergen skin
test reactivity. Measurement of pulmonary function and
reversibility with a short-acting b2-agonist will be done
at 8 years of age. Wheezing illness will be defined as
wheeze in the previous 12 months.
Secondary study outcomes-immunological outcomes
Five possible mechanisms have been defined that could
mediate the putative effects of geohelminth infections
on the primary study outcomes. A justification for
choosing these mechanisms is provided in the
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Discussion. The mechanisms are: 1) Th2 polarization-
measured by the ratio of IL-5 to IFN-g protein produced
by peripheral blood leukocytes (PBLs); 2) immune
homeostasis-production of IL-10 spontaneously in 5-day
PBL cultures [50]; 3) immune suppression-antigen-spe-
cific suppression measured by frequencies of IL-10+CD4
+ T cells or IL-10 production by antigen-stimulated
PBLs [51-53] or ‘bystander suppression’ measured by IL-
10 production by A. lumbricoides antigen-stimulated
PBLs [54,55]; 4) immune maturation-capacity of PBLs to
produce IFN-g to sub-optimal stimulus with Staphylo-
coccal enterotoxin B (SEB); and 5) pro-inflammatory
responses-IL-8 production by PBLs stimulated with LPS
[56], and quantities of IL-17, IFN-g, and IL-5 produced
by SEB-stimulated PBLs. Flow cytometry experiments
will be performed using cryopreserved and fixed periph-
eral blood leukocytes using standardized protocols
[41,56,57].
For each of the outcomes, the following mechanisms will
be evaluated
1. Vaccine immunity: Immunological outcomes will be
measured at 24 months (short-term immunity) and 5
years (long-term immunity) for Th2 polarization (teta-
nus toxoid [TT] and tuberculin [PPD]-stimulated PBLs),
immune homeostasis, and immune suppression (IL-10
production by PBLs stimulated with TT, PPD, and A.
lumbricoides antigen).
2. Atopy: Immunological outcomes will be measured
at 5 years for immune homeostasis and immune sup-
pression (frequencies of IL-10+CD4+ T cells [ISC only]
or IL-10 production by PBLs stimulated with D. ptero-
nyssinus, P. americana, and A. lumbricoides antigen).
3. Eczema: Immunological outcomes will be measured
up to 3 years for markers of immune maturation,
immune homeostasis, immune suppression (frequencies
of IL-10+CD4+ T cells (ISC only) or IL-10 production
by A. lumbricoides-stimulated PBLs), and pro-inflamma-
tory responses (ISC only).
4. Asthma: Immunological outcomes will be measured
at 5 years for markers of immune homeostasis, immune
regulation/suppression (frequencies of IL-10+CD4+ T cells
[ISC only] and IL-10 production by PBLs stimulated with
D. pteronyssinus and A. lumbricoides antigen), Th2 polari-
zation (ratio of IL-5 to IFN-g to sub-optimal SEB stimu-
lus), and pro-inflammatory responses (ISC only).
Study limitations
We expect losses to follow-up to be up to 10% in the
first year (i.e. 2,163/2,403 followed up) and 5% annually
to age 3 and a further 5% between ages 3 and 5.
Estimates for the number of children followed-up are: 2
years-2,055, 3 years-1,952, and 5 years-1,854. Losses are
due to the mobility of the study population.
Potential sources of biases are selection bias caused by
losses to follow up and information bias caused by sys-
tematic misclassification of outcomes. The following
methods are being used to minimize these biases:
Achieving high rates of follow-up - a) we have a well-
trained study team employed full-time for the cohort; b)
we conduct regular home visits to maintain contact with
study mothers; c) the universal use of mobile phones
allows us to maintain regular contact with study
mothers; d) the mother of each child is given a cohort
identification card with a phone number to make
appointments at the ECUAVIDA outpatient Clinic;
e) changes of address are followed up actively with
home visits to repeat environmental sampling. Informa-
tion bias - a) repeated measurements of outcomes (for
asthma, eczema, and allergen skin test reactivity) should
reduce misclassification and recall bias; b) clear defini-
tions for primary outcomes and exposures; c) evaluation
of outcomes is being performed blind to exposure
status. Detailed information on potential confounding
factors is being collected.
Study power
The study sample size is fixed at 2,403 newborns. Pri-
mary outcome variables will be treated as statistically
independent. Power calculations for primary study ques-
tions are shown in Table 2[58,59]. We expect a high
degree of power for the estimation of most primary and
secondary study outcomes (≥ 80% depending on immu-
nological mechanism at a = 0.01) that will allow for the
loss of power expected by controlling for confounding.
Analysis plan
Statistical analysis will be guided by the conceptual
frameworks presented for each of the study outcomes
(Figures 2, 3, 4 and 5). The analysis of the primary
study outcomes will use multiple logistic regression to
estimate the Odds Ratios for exposure-outcome associa-
tions with adjustment for appropriate confounding fac-
tors. For example, a priori confounders for the
association between maternal geohelminth infections
and eczema by 3 years of age are gender, maternal edu-
cational level, household crowding, and infant geohel-
minth infections. The primary analyses will evaluate the
effects of maternal geohelminth infections or infant
geohelminth infections on: 1) protective immunity to
common childhood vaccines: 2) the presence of allergen
skin test reactivity at 5 years of age; 3) the development
of eczema by 3 years of age; and 4) the development of
asthma at 5 and 8 years of age. Immunological variables
will be defined as binary variables with a cut-off defined
by the limit of detection of the assays (i.e. IL-10) or
median level (i.e. IL-8) or as loge-transformed continu-
ous variables. Because immunological variables are
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considered as intermediate in the causal pathways
between exposures and outcomes, these variables will be
evaluated in hierarchical analyses [60].
Information, ethical approval, consent, and ethical
considerations
The Ministry of Health in Ecuador was informed of the
study and gave its support for the study in Esmeraldas
Province, Ecuador (Subsecretaria General de Salud,
reference SSG-10-000285). Formal recruitment into
study occurred at the first home visit done during
before the child was 14 days old. Informed consent for
the collection of samples during the study before this
time was done at 2 different time points: 1) antenatal
clinic visit for collection of a stool and blood samples:
2) in the maternity department of HPAB for collection
of maternal stool and blood samples, cord blood and
meconium. At each of the three times at which written
consent was obtained, the mother received both written
and verbal information in Spanish on the aims of the
study and the reasons for collection of study samples.
Results are provided to the mother for all clinical sam-
ples collected. Where necessary, the child will be evalu-
ated by a study physician, and appropriate medication
and nutritional supplements provided as required
through the ECUAVIDA study clinic at HPAB. Appro-
priate antiparasite treatment is given for all stool sam-
ples with documented geohelminth infections.
Benzimidazole drugs are not given to pregnant women
or children before 2 years of age following the recom-
mendations of the Ecuadorian Ministry of Health.
Infected mothers are offered albendazole when breast-
feeding has finished. Infected children aged below 2
years are treated with pyrantel and after 2 years with
albendazole. Infections with Giardia intestinalis and
Entamoeba histolytica are treated with a standard course
of metronidazole if characteristic trophozoites are
observed. The study protocol was approved by the
Ethics Committees of the Hospital Pedro Vicente Mal-
donado and the Universidad San Francisco de Quito,
and is registered as an observational study (ISRCTN
41239086).
Although anthelmintic treatment is a highly popular
intervention, clear health benefits from the treatment of
pregnant women have not been unequivocally demon-
strated, and such benefits could be argued to be at best
marginal in most endemic regions where hookworm
anaemia is relatively infrequent and geohelminth
Table 2 Power for analysis of primary exposure-outcome associations
Primary exposures
(geohelminth infections)
Outcome Sample size
available
Analysis
sample size
Exposure
prevalence
Expected prevalence of
outcomes
(exposed vs.
unexposed groups)
Α Power
Maternal Vaccine antibodies
@ 7 mths
Hib 2,300 1,000 50% 65% vs. 75% 0.01 80%
Rotavirus 2,300 1,000 50% 40% vs. 60% 0.01 > 99%
Maternal Vaccine antibodies
@ 2 yrs
TT 1,955 1,000 50% 85% vs. 95% 0.01 > 99%
HBV 1,955 1,750 50% 80% vs. 85% 0.05 80%
OPV type 3 1,955 500 50% 80% vs. 95% 0.01 > 99%
Infant Vaccine antibodies
@ 5 yrs
TT 1,725 1,000 35% 60% vs. 80% 0.01 99%
HBV 1,725 1,500 35% 70% vs. 80% 0.01 95%
OPV type 3 1,725 1,000 35% 50% vs. 70% 0.01 > 99%
Maternal SPT @ 3 years 1,840 1,840 50% 15% vs. 25% 0.01 99%
Infant SPT @ 3 years 1,840 1,840 35% 15% vs. 25% 0.01 > 99%
Maternal Eczema @ 3 years 1,840 1,840 50% 25% vs. 35% 0.01 99%
Maternal Asthma @ 5 years 1,725 1,725 50% 17% vs. 23% # 0.05 86%
Infant Asthma @ 5 years 1,725 1,725 35% 17% vs. 23% # 0.05 83%
Infant Asthma @ 5 years 1,725 1,207 20% 25% vs. 15% # 0.01 93%
Random samples of the study population will be selected for analysis of the protective levels of vaccine antibodies. Based on data from the cohort we estimate
that 20% of children will have allergen skin test reactivity to any allergen at 5 years, that 30% of children will have at least one documented episode of eczema
by 3 years of age and that 20% of children will have asthma at 5 years. Based on data from the cohort we estimate that ~50% of mothers are infected with any
geohelminth parasite and ~30% of children will have at least one documented geohelminth infection during the first 2 years of life.
#-expected effects of geohelminth infections on asthma prevalence using data from cross-sectional analyses in Ecuador [58] and Brazil [59].
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Figure 2 Conceptual model for effects of maternal and infant geohelminth infections on vaccine immune responses measured at 7
months, 2 years or 5 years. Maternal infections would be expected to mediate effects on vaccine responses at 7 months and 2 years,
although infant infections, generally acquired during the second year of life, may contribute to effects at 2 years. The suppressive effects of
infant infections would be expected to be most important at 5 years. Potential immunological mechanisms that may mediate the suppressive
effects of geohelminth exposures are shown in dashed boxes.
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Figure 3 Conceptual model of effects of maternal and infant geohelminth infections on allergen skin test reactivity. The effects of both
exposures are presumed to occur via the development of a modified Th2 (mTh2) response during chronic geohelminth infection. A modified
Th2 response may affect allergen skin test reactivity through 2 distinct mechanisms: 1) a direct effect on mast cell function independent of
aeroallergen-specific IgE resulting in an increased threshold for activation through enhanced production of spontaneous or geohelminth-induced
IL-10. Such effects would be predicted to effect wheal sizes non-specifically including the histamine positive control. 2) An indirect effect on
mast cell function by attenuation of the association between specific IgE and skin test reactivity. This effect would be predicted to be
aeroallergen-specific, affect only those wheals for which an individual has significant levels of specific IgE (at > 0.35 kU/L) but not the positive
control, and be mediated by aeroallergen-induced IL-10. The effect could also be mediated by geohelminth-induced IL-10 for aeroallergens
where the IL-10-stimulating allergens share significant immunological cross-reactivity with helminth allergens.
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Figure 4 Conceptual model for the effects of maternal and infant geohelminth infections on asthma in children. The effects of these
exposures on asthma are considered to occur via effects on bronchial hyperreactivity. The protective effects of chronic helminth exposures
(maternal and infant infections within the first 2 years of life) are presumed to occur via the development of a modified Th2 (mTh2) response
that may affect bronchial hyperreactivity through: 1) Immune regulation/suppression-suppression of airways inflammation via enhanced
production of geohelminth or aeroallergen-induced IL-10. 2) Homeostasis-enhanced production of spontaneous IL-10 will suppress airways
inflammation non-specifically. Alternatively children without early geohelminth exposures and that are first exposed to infection after 2 years of
age (> 24 m) may respond to A. lumbricoides infection with strong inflammatory responses in the airways that up-regulate pro-inflammatory
pathways including Th1, Th2, and Th17. The modified Th2 response will be defined by the presence of specific IgG4 antibodies to geohelminths.
RTIs- respiratory tract infections. ETS-environmental tobacco smoke.
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Figure 5 Conceptual model for the effects of maternal geohelminth infections on eczema. Effects of maternal geohelminth exposures on
eczema are considered to occur through the capacity of the immune system to regulate inflammation of the skin caused by external insults.
Factors that may determine the ability of the immune system to do this include: 1) Immune maturation-the speed of maturation of the immune
response in early life is likely to effect the ability of the immune response to respond to infections and other insults with appropriate but
measured inflammatory responses. 2). Immune regulation/suppression-the development of robust and specific immune regulatory mechanisms
are important for the development of an appropriate inflammatory response to specific insults. 3) Immune homeostasis-robust mechanisms to
limit responses to pro-inflammatory stimuli may be an importance mechanism for the control of inflammation.
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infections are low intensity [61]. For this reason, we
opted for an observational rather than an interventional
design that would allow us to understand the natural
history of the interaction between early geohelminth
exposures and the study outcomes, but provide the
opportunity to identify potential interventions that could
be beneficial and be evaluated in future intervention
studies.
Discussion
The ECUAVIDA cohort study has been designed to
investigate the potential impact of early exposures to
geohelminth infections during pregnancy and in the first
2 years of life on protective immunity provided by
widely used infant vaccinations and on the development
of allergic sensitization and allergic diseases. The present
study is one of several observational and intervention
studies [18,35] currently in progress that will inform
public health policy of the potential effects of early
exposures to these parasites on a number of health out-
comes and the potential benefits as well as risks of pro-
viding anthelmintic drugs during pregnancy and infancy
in areas where these parasites remain highly prevalent.
Adequate evidence to support changes in public health
policy will require studies to be conducted in different
geographic settings and among different populations
with varying prevalence of geohelminth parasites.
Potential effects of geohelminth infections on vaccine
immune responses
Currently, the most effective public health intervention
aimed at reducing infectious disease deaths in under-5s
is infant vaccination. Several vaccines are recognized to
be less immunogenic in poor populations [7,8,10,62-66]
requiring an increase in the dose or number of doses
administered to achieve adequate vaccine immunity
[7,67]. Poor vaccine immunogenicity is a problem for
mucosal vaccines such as OPV and rotavirus both of
which have proved to be less immunogenic in poor
compared to wealthier populations [9,10,68,69]. In the
case of OPV, poor vaccine immunity is most marked to
OPV type 3 [7,70,71], and as many as 11 doses of OPV
may be required to achieve 90% seroconversion [72].
Factors contributing to poor responses to vaccines may
include overcrowding, poor sanitation, high-titer mater-
nal antibodies, micronutrient malnutrition, environmen-
tal enteropathy and co-infections [8,73,74]. The relative
importance of these factors in affecting vaccine immune
responses may vary between vaccines.
Geohelminth infections have deleterious effects on
vaccine immunity to oral [32,75] and parenteral vaccines
[30,31] in children, and there is growing evidence from
experimental animal models that concurrent parasite
infections have important suppressive effects on vaccine
immune responses [25,76,77]. Most human studies to
date have been conducted in school age children or
adults. There are few data from studies investigating the
effects of maternal geohelminth infections on vaccine
immune responses in infancy. Such studies have evalu-
ated effects of maternal helminth infections and have
provided evidence for a suppressive effect of maternal
infection on IFN-g responses to mycobacterial antigens
in newborns [40] and IgG antibody responses to Hae-
mophilus influenzae type b vaccine (Hib) at 6 months of
age [31].
The immunological mechanisms by which such infec-
tions mediate these effects are poorly understood. Geo-
helminth exposures may suppress vaccine immune
responses through three possible immunological
mechanisms (Figure 2): 1) Th2 polarization-with a
switch in Th1 towards Th2 responsiveness causing
reduced Th1 responses (i.e. IFN-g) responses important
for antiviral immunity and immunity against bacterial
infections (e.g. Mycobacteria [78]and Bordetella pertus-
sis [79]). Such a mechanism would predict an overall
and non-specific Th2-biassed response to both vaccine
and other antigens with a failure to develop ‘protective’
Th1 vaccine responses. 2) Immune homeostasis-attenu-
ated immune responses caused by strong homeostatic
mechanisms such as increased spontaneous production
of IL-10 associated with chronic geohelminth infections
[80]. Such effects would be expected to suppress Th1
and Th2 immune responses to vaccines and may result
in an increased threshold for the activation of immune
responses. 3) Immune suppression-this could be anti-
gen-specific or caused by bystander suppression. Pre-
vious studies have demonstrated that the suppression of
immunity to TT in vaccinated subjects infected with
Onchocerca volvulus [51] and Wuchereria bancrofti [52]
is mediated in part by TT-specific IL-10. Alternatively,
strong regulatory responses to helminth antigens asso-
ciated with enhanced geohelminth antigen-induced IL-
10 [80] may inhibit immune responses to unrelated vac-
cine antigens through bystander suppression.
Potential effects of geohelminth infections on
allergic sensitization
Childhood geohelminth infections are inversely asso-
ciated with allergen skin test reactivity [81-87]. This
observation has led to the suggestion that anti-parasite
immune modulatory mechanisms may suppress allergic
inflammatory responses to aeroallergens. However, the
findings of intervention studies in which children
infected with geohelminths have received anthelmintic
treatment are contradictory. Different intervention stu-
dies have provided evidence for an increased incidence
[88] or prevalence [55,89,90] of allergen skin test reac-
tivity after periodic anthelmintic treatments, but a large
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cluster-randomized trial of periodic anthelmintic treat-
ment in Ecuador did not observe a change in the preva-
lence of allergen skin test reactivity after treatment [91].
The contradictory findings of different studies could be
explained by differences in the prevalence of geohel-
minth parasites between different geographic regions,
the period for which anthelmintic treatment was given,
the effects of early exposures to geohelminths in pro-
gramming anti-allergic responses [5,39], or treatment
effects on other endemic helminth infections (e.g.
Toxocara).
The presence of geohelminths during pregnancy may
modify the immune responses of offspring in utero [41].
The possible protective effects of environmental expo-
sures such as geohelminths against allergy may be stron-
gest when they occur in the first year or two of life [92].
We have hypothesized that early exposures to geohel-
minths may programme the infant immune system for
reduced allergy [39]. Such programming may not be
reversible (i.e. by anthelmintic treatment in later child-
hood) and could be ‘reinforced’ later by active regulatory
mechanisms induced by heavy helminth infections
(reversible by anthelmintic treatment) [39]. Evidence in
support of this hypothesis has come from a recent
observational study in Brazil showing that early and
heavy exposures to T. trichiura protected against aller-
gen skin test reactivity later in childhood independent of
later infections [93].
The immunological mechanisms by which chronic geo-
helminth infections may suppress IgE-mediated hypersen-
sitivity measured by allergen skin test reactivity are
illustrated in Figure 3. Maternal geohelminth infections,
augmented by infections in infancy, may have indirect sup-
pressive effects on immediate hypersensitivity responses in
the skin through effects on immune homeostasis. Chronic
geohelminth infections in children are associated with an
increased accumulation in vitro by unstimulated PBLs of
the anti-inflammatory cytokine IL-10 [50]. A previous
study of children from Cameroon infected with A. lumbri-
coides and T. trichiura provided evidence for an inverse
association between geohelminth infection intensity and
immune reactivity that was associated with enhanced pro-
duction in vitro of IL-10 and TGF- b1 by unstimulated
PBLs [94]. Further, a study of children in poor neighbor-
hoods in Salvador, Brazil has shown that the presence of
detectable spontaneous IL-10 is associated with poor
access to sanitation [95] and geohelminth infections in
early childhood [80]. Elevated ‘homeostatic’ production of
IL-10 by immune cells may suppress immune reactivity
[5]. IL-10 has been shown previously to suppress mast cell
activation [96] and be inversely associated with wheal size
to allergen skin tests [97].
In populations living in environments endemic for
geohelminth infections, there is a strong disassociation
between the presence of allergen-specific IgE in serum
and skin test reactivity to the same allergen
[57,82,98,99]. Environmental exposures including geo-
helminth infections are likely to be major determinants
of this relationship. Geohelminth infections may affect
the association between allergen-specific IgE in serum
and skin test reactivity through enhanced production of
helminth antigen-induced [54], aeroallergen-induced
[53], or spontaneous IL-10 [50]. Increased IL-10, what-
ever the cellular source, may suppress mast cell activa-
tion in the skin, thereby reducing the prevalence of
allergen skin test reactivity. The effects of maternal geo-
helminth or early infant infections on levels of allergen-
specific IgE are not clear. A high proportion of children
living in the rural Tropics appear to have low-affinity
IgE to aeroallergens (e.g. 0.35-0.7 kU/L) that can be
only be partially absorbed by pre-incubation with the
specific allergen [98] and may represent cross-reactive
anti-helminth IgE antibodies [100,101].
Potential effects of geohelminth infections on the
development of allergic inflammatory diseases
Asthma is a heterogeneous disease caused by complex
interactions between host genetics and environment.
Rural residence appears to be strongly protective against
the development of allergic disease that may be
mediated by common exposures present in the rural
environment [102], particularly in early life [90]. Early
infections are considered to be particularly relevant
[92,103-107]. Geohelminth infections in childhood are
inversely associated with asthma symptoms [34] or spe-
cifically asthma associated with atopy [87] in some
populations that are highly endemic for these parasites.
The effects of different geohelminths parasites on
asthma may be distinct [34]. However, there is also
growing literature that points to a role of helminths,
particularly A. lumbricoides, as a risk factor for asthma
in populations with a low prevalence of infection
[108-114].
Atopy has been consistently linked to asthma in devel-
oped countries but there is evidence that the association
between asthma and atopy in developing countries is
weaker [87,98,115-117]. An explanation for this observa-
tion is that is that the more prevalent infectious expo-
sures including geohelminth infections present in many
developing countries may attenuate the association
through a reduction in allergic sensitization.
The mechanisms by which geohelminth infections
may affect inflammatory disease of the airways are illu-
strated in Figure 4. A predisposition to inflammation of
airways and the pathological sequelae (e.g. airways
remodeling) may arise from an interaction between
genetic and undefined early life in utero exposures
[118]. The subsequent development of asthma may be
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associated with or without atopy (so-called atopic and
non-atopic asthma). Because chronic geohelminth infec-
tions have important modulatory effects on allergic
inflammation [5], it is likely that protective exposures
mediate their effects by suppression of allergic inflam-
mation through the ‘atopic’ pathway (Figure 4). The
mechanisms that mediate this effect are unlikely to be
restricted to the lungs-experimental animal models of
the effects of intestinal helminths on tissue inflamma-
tion have shown that infections can ameliorate inflam-
matory disease in several different tissues (e.g. the
intestine, liver, and lungs [4,119-121]. Relevant mechan-
isms are likely to be generalized and may include effects
on immune homeostasis (i.e. increased spontaneous IL-
10) and regulation (i.e. elevated frequencies of adaptive
T regulatory cells expressing IL-10 [Tr1 cells]). Migra-
tory Ascaris larvae in populations where A. lumbricoides
infections are sporadic or low-prevalence populations
may induce inflammation directly in the lungs or
enhance other inflammatory processes (e.g. inflamma-
tion caused by exposure to environmental tobacco
smoke or respiratory tract infections: Figure 4).
Eczema is a chronic relapsing inflammatory skin dis-
ease that may be caused by an impaired ability to regu-
late inflammation induced by environmental insults in
the presence of impaired skin barrier function [122].
Eczema generally develops within the first 6 months of
life [123], peaks in prevalence between 2 and 3 years
[124], after which the prevalence declines [125]. Little is
known of the natural history of eczema in tropical
environments with respect to prevalence, severity, envir-
onmental risk factors, and associations with atopy. The
association between eczema and geohelminth infection
is controversial [126] and studies have shown both posi-
tive [127] and negative [128-130] associations. An inter-
vention study in Uganda provided evidence that
treatment of geohelminths during pregnancy was asso-
ciated with a reduced risk of eczema at 1 year [130].
Infants of infected mothers in the placebo group had a
reduced prevalence of eczema compared to those of
non-infected mothers [130].
The mechanisms by which geohelminth infections
may reduce the risk of eczema are not known. Possible
mechanisms are illustrated in Figure 5. The strongest
effects are likely to be mediated by maternal infections
because the disease often appears before infant geohel-
minth infections are acquired. The clinical presentation
of eczema is a direct consequence of the damage caused
by repeated scratching of the skin. Eczema, may there-
fore, be caused by numerous external insults that cause
pruritus. A novel finding is that children born in the
rural Tropics rapidly down-regulate pro-inflammatory
responses to innate immune stimuli [56]. Such age-
dependent responses are likely to be important adaptive
mechanisms by which an early capacity to respond to
innate immune stimuli that may be important in the
absence of adaptive immunity but associated with an
increased risk of pathologic inflammation, is rapidly
down-regulated once specific adaptive immune
responses have developed. We hypothesize, therefore,
that the protective effects of maternal geohelminth
infections are likely to be associated with markers of
early immune maturation and mediated by non-specific
and generalized anti-inflammatory effects (e.g. increased
spontaneous IL-10) and regulation of innate (i.e.
reduced IL-8 production to TLR agonists) and adaptive
(i.e. elevated frequencies of induced regulatory T cells [i.
e. CD4+IL-10+ Tr1 cells]) immunity.
Conclusion
The present study will investigate the possible effects of
maternal and infant infections with geohelminth para-
sites on vaccine immunity, and the development of
atopy and the allergic diseases, eczema and asthma. A
greater understanding of the impact of geohelminth
exposures on vaccine immune responses is likely to lead
to the development of new interventions designed at
enhancing vaccine immunogenicity among neglected
populations where these infections are endemic espe-
cially since these populations bear a disproportionate
burden of vaccine-preventable infectious diseases.
Although eczema and asthma are major public health
problem of childhood worldwide, relatively little is
known of causal immunological mechanisms in tropical
populations where the predominant disease phenotypes
(e.g. non-atopic asthma) may be distinct. The present
study will collect epidemiological and immunological
data prospectively from birth to understand how early
geohelminth exposures alter inflammatory and regula-
tory responses to affect the development of these
inflammatory diseases. Results of this study will inform
prevention strategies that could be designed to mimic
the beneficial immunological effects of geohelminth
infection in the absence of actual infection.
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